Cardio-Renal Registry

Launched by QUEEN MARY UNIVERSITY OF LONDON · Jul 22, 2024

Keywords

ClinConnect Summary

The Cardio-Renal Registry is a clinical trial that aims to better understand how heart disease affects patients with severe kidney disease. This study is important because heart problems are the leading cause of illness and death in people with chronic kidney disease (CKD). Even if patients have other health issues like diabetes or high blood pressure, their risk for heart disease increases as their kidney function worsens. Unfortunately, patients with both heart and kidney issues often receive less treatment than those without kidney disease, which could be due to concerns about potential side effects. This trial will gather information on these patients to help predict outcomes and improve their care.

To be eligible for this study, participants need to be at least 16 years old and have kidney disease that is being managed by the Nephrology team. The trial will automatically include patients in a research database, so they don’t need to give consent individually. This study will not include children and will also involve vulnerable adults who are unable to give consent but are under the care of the Nephrology team. Participants can expect their health data to be used to help improve how doctors understand and treat heart disease in those with kidney problems.

Gender

ALL

Eligibility criteria

• • Informed consent will not be sought for, as patients are automatically included onto a database that we will use for research purposes. No children will be included in this study. Vulnerable adults or those unable to give consent will be included in the study as well if they are referred to the Nephrology team.
• Inclusion Criteria:
• • 1. Both male and female patients ≥16 years of age will be included
• • 2. All patients will be reviewed by the Nephrology team a the RLH with renal disease.
• Exclusion Criteria:
• • 1. Patients \<16 years will not be included in this study.